Fig. 3. Effects of peginterferon-α-2a and ribavirin exposure on sustained virological response (SVR). The cumulative exposure of patients to the study drug(s) was expressed as a percentage of the planned total dose.

severe fibrosis stage was reported in only 15.6% of patients. As a result, the small proportion of patients with severe fibrosis staging may have influenced the outcome of the current analysis.

Anaemia is a common adverse effect that can occur soon after the initiation of treatment with PEG IFN plus ribavirin for HCV infections. This complication can negatively impact patient quality of life, and is the most common reason for dose reductions and the temporary or permanent discontinuation of ribavirin. Such dose modifications have been shown to reduce the efficacy of treatment.[12] In general, females were predicted to have a higher likelihood of becoming anaemic than male patients.[13] In addition, the dose reduction rate of PEG IFN-α-2a and ribavirin is higher in elderly patients, which negatively impacts the achievement of an SVR.[5]

In a recent pooled analysis[14] of two phase III trials of 48 weeks of treatment with PEG IFN-α-2a plus ribavirin, the SVR rate was significantly reduced (p = 0.0006) in patients with a cumulative ribavirin dose of <60%. Prolonged periods of dose reduction, temporary interruptions or premature cessation of ribavirin were also associated with decreased SVR rates.

Previous studies have not assessed the impact of reducing the dose of PEG IFN independent of riba-

virin, or differentiated between dose reduction, or interrupting or prematurely discontinuing treatment. An analysis of the HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial[15] investigated the impact of PEG IFN-α-2a and ribavirin dose reductions during the retreatment of patients infected with chronic HCV genotype 1 who did not respond to standard IFN with or without ribavirin treatment. A decrease in the cumulative dose of PEG IFN-α-2a received during the first 20 weeks of treatment (lead-in phase), from full dose (≥98%) to ≤60%, reduced the SVR rate from 17% to 5%. In contrast, reducing the dose of ribavirin from full dose to ≤60% did not affect the SVR rate as long as ribavirin administration was not interrupted for more than seven consecutive days. However, the premature discontinuation of ribavirin, even with full-dose PEG IFN-α-2a, reduced the SVR rate to 3%. This suggests that sufficient dosage during the early stages of therapy is required to achieve a high SVR rate with combination therapy. In our study, the SVR rate was also reduced in patients who received cumulative PEG IFN-α-2a and ribavirin doses of <60%, which was further decreased in patients who discontinued combination therapy. Therefore, it is important to alter the way adverse events of PEG IFN-α-2a and ribavirin therapy are managed to minimize the number of patients needing to reduce doses or discontinue therapy.

Conclusion

The attainment of an SVR following PEG IFN-α-2a plus ribavirin combination therapy was not influenced by any of the host-related factors evaluated in this analysis, although males aged ≥60 years tended to have a lower SVR rate. In contrast, younger age, male sex and lower baseline HCV RNA levels significantly increased the likelihood of achieving SVR with monotherapy. Dose reductions had a negative impact on SVR in elderly patients receiving combination therapy. Therefore, it is important to minimize PEG IFN-α-2a and ribavirin dose reductions by effectively managing treatment-related adverse events in elderly patients.

Acknowledgements

References

1. Tanaka Y, Hanada K, Mizokami M, et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584-9

2. Hamada H, Yatsuhashi H, Yano M, et al. Impact of aging on the development of hepatocellular carcinoma in patients with post-transfusion chronic hepatitis C. Cancer 2002; 95: 331-9

3. Kuboki M, Iino S, Okuno T, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22: 645-52

4. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-91

5. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63

6. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9

7. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9

8. Dosmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, staging. Hepatology 1994; 19: 1515-20

9. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71

10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65

11. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-6

12. McHutchison JG, Manns MP, Brown RS. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9

13. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62: 699-709

14. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-9

15. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12

Correspondence: Dr *Gotaro Yamada*, Department of Internal Medicine, Kawasaki Medical School, Center for Liver Diseases, Kawasaki Hospital, Okayama City 2-1-80, Okayama, 700-0986, Japan.

E-mail: g.yamada@kawasaki-hp.jp

HEPATITIS

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

Masao Omata, Haruhiko Yoshida, Joji Toyota, Eiichi Tomita, Shuhei Nishiguchi, Norio Hayashi, Shiro Iino, Isao Makino, Kiwamu Okita, Gotaro Toda, Kyuichi Tanikawa, Hiromitsu Kumada, for the Japanese C-Viral Hepatitis Network

See end of article for authors' affiliations

Correspondence to:
Professor Masao Omata, Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo, Tokyo 113-8655, Japan; omata-2im@h.u-tokyo.ac.jp

Background: Combined pegylated interferon and ribavirin has improved chronic hepatitis C (CH-C) therapy; however, sustained virological response is achieved in only about half of the patients with a 1b genotype infection. We assessed oral ursodeoxycholic acid (UDCA) on serum biomarkers as a possible treatment for interferon non-responders.

Methods: CH-C patients with elevated alanine aminotransferase (ALT) were assigned randomly to 150 (n = 199), 600 (n = 200) or 900 mg/day (n = 197) UDCA intake for 24 weeks. Changes in ALT, aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) were assessed. This study is registered at ClinicalTrial.gov, identifier NCT00200343.

Results: ALT, AST and GGT decreased at week 4 and then remained constant during drug administration. The median changes (150, 600 and 900 mg/day, respectively) were: ALT, -15.3, -29.2 and -36.2%; AST, -13.6, -25.0 and -29.8%; GGT, -22.4, -41.0 and -50.0%. These biomarkers decreased significantly less in the 150 mg/day than in the other two groups. Although changes in ALT and AST did not differ between the 600 and 900 mg/day groups, GGT was significantly lower in the 900 mg/day group. In subgroup analysis, ALT decreased significantly in the 900 mg/day group when the baseline GGT exceeded 80 IU/l. Serum HCV-RNA did not change in any group. Adverse effects were reported by 19.1% of the patients, with no differences between groups.

Conclusions: A 600 mg/day UDCA dose was optimal to decrease ALT and AST levels in CH-C patients. The 900 mg/day dose decreased GGT levels further, and may be preferable in patients with prevailing biliary injuries.

Chronic hepatitis C (CH-C) is a common liver disease worldwide. The prevalence of hepatitis C virus (HCV) infection increased recently in several countries[1] and has now resulted in a growing incidence of HCV-related hepatocellular carcinomas.[2][3] Following the discovery of HCV, interferon therapy was established as the only treatment to eliminate the viral infection. The introduction of combination therapy with pegylated interferon and ribavirin has substantially enhanced the efficacy of antiviral therapy.[4][5] However, the HCV genotype 1b, the major genotype in Japan, is refractory even to this combination therapy and only shows sustained virological response rates of about 50%. Moreover, interferon therapy is sometimes contraindicated or stopped early due to haematological, psychological and other complications.

Ursodeoxycholic acid (UDCA) is a hydrophilic stereoisomer of chenodeoxycholic acid which was used first to dissolve cholesterol gallstones and recently to treat primary biliary cirrhosis.[6][7] In 1985, Leuschner et al reported a decrease in serum aminotransferase levels in patients with HBV-negative chronic hepatitis who were given UDCA for concomitant gallstones.[8] Traditional Chinese medicine uses ursine bile for liver diseases; it contains plentiful UDCA and inspired the chemical name. Semi-synthetic UDCA became commercially available in Japan in 1957 and has been used since then for chronic liver disease. In 1994, Takano et al reported a randomised, controlled-dose study of UDCA for CH-C: 57 patients were assigned randomly to take 150, 600 or 900 mg/day of UDCA and compared with 17 control patients.[9] The authors showed that serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) decreased less with 150 mg/day, the dose recommended by the Japanese national health insurance policy at that time, than with 600 or 900 mg/day, while the results with the latter two doses were similar. Although the effects of UDCA on fibrosis progression rates have not been established, the strong association between serum ALT levels and fibrosis progression rates has been well documented,[10][11] and it can be speculated that a decreased ALT level is associated with delayed fibrosis progression. Thus, the present study was conducted primarily as a dose-finding trial, using the changes in ALT levels as the primary endpoint.

PATIENTS AND METHODS

Patients

Patients with CH-C who were 20 years of age or older and tested positive for HCV-RNA or HCV core proteins were recruited as candidates for this study. They were observed for 8 weeks prior to administration of the drug, and those who showed ALT of 61 IU/l or higher in week −4 were enrolled. Patients were excluded from the study if they had received antiviral treatment (interferon with or without ribavirin) within 20 weeks before the observation period or were treated with corticosteroids, immunosuppressive drugs, glycyrrhizic acid, cholestyramine or other drugs that may affect liver function or interfere with UDCA metabolism. Patients were also excluded if they: i) had decompensated cirrhosis, viral hepatitis

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CH-C, chronic hepatitis C; GGT, gamma-glutamyl transpeptidase; HCV, hepatitis C virus; UDCA, ursodeoxycholic acid

other than hepatitis C, autoimmune liver disease, alcoholic or drug-induced liver injury, malignant tumour, biliary disorder, fulminant hepatitis or peptic ulcer; ii) required hospitalisation for cardiac, renal or pancreatic disease; iii) were pregnant or lactating; iv) alcohol dependent or drinking more than approximately 22 g/day alcohol; v) were participants in another clinical study within 4 weeks before the observation period; or vi) were sensitive to UDCA or other bile acid preparations.

The protocol was approved by the ethics committee of each institution participating in the study. Patients were informed of the details of the clinical study and agreed to participate. We conducted this clinical study in accordance with the Declaration of Helsinki and good clinical practice.

Study design
After the 8-week observation period patients were treated with oral (prandial) UDCA (Urso, Mitsubishi Pharma, Osaka, Japan) for 24 weeks at 150, 600 or 900 mg/day, divided into three doses, under double-blind conditions. Double blinding used placebo, 50 and 100 mg tablets identical in appearance to the test drug. The UDCA doses were established from a previous clinical study of UDCA in patients with CH-C.[9] Concomitant use of drugs and therapies included in the exclusion criteria were prohibited throughout the observation and treatment periods.

Changes in serum ALT levels were previously reported to be −26% and −25.5% with 600 and 900 mg/day of UDCA, respectively, compared to untreated controls and no significant changes were observed with 150 mg/day.[9] Based on these data, we assumed a standard deviation of 30% for per cent changes in ALT, and the necessary sample size was calculated to be 200 in each group to detect any superiority of the 600 and 900 mg/day doses over 150 mg/day at a significance level of 0.05 and a power of 0.9.

We enrolled patients who met all criteria and gave written informed consent between July 2002 and May 2004 in 62 institutions with liver clinics throughout Japan. Each patient was assigned randomly to one of the three dose groups by using numbered containers provided based on a permuted block method (block size: 6).

When treatment or evaluation was discontinued because of patient request, aggravation of symptoms, adverse events or other reasons, prior data were included in the evaluation as final observation data.

To investigate the long-term effects of UDCA, the protocol included an option for additional UDCA administration for a minimum of 28 weeks and a maximum of 80 weeks (total 52–104 weeks including the initial 24 weeks) if the ALT level had decreased by at least 15% at week 20 compared to the baseline. In the additional period, the double-blind setting was discontinued and the dose of 600 mg/day was adopted, which could be increased to 900 mg/day by the decision of each patient and the physician responsible. Patients who entered the additional phase could discontinue UDCA administration anytime after week 52.

Laboratory tests
Blood was collected every 4 weeks from the start of the observation period to the end of drug administration. Serum ALT was measured as a primary endpoint of liver function, and AST and GGT as secondary endpoints, using conventional methods. Blood samples taken at the start of observation, at 0, 4 and 12 weeks of treatment, and at the final observation were analysed to determine leukocyte and erythrocyte counts, haemoglobin, haematocrit, thrombocyte count, and the levels of ALT, AST, GGT, alkaline phosphatase, lactate dehydrogenase, total protein, albumin, cholinesterase, total bilirubin, direct

bilirubin, total cholesterol, urea nitrogen, creatinine, Na, K and Cl.

For bile acid composition analysis, blood was collected at the start of treatment and at the final observation in a fasted condition. Serum total bile acid was measured by the 3α-hydroxysteroid dehydrogenase method. Bile acid fractions were determined by a specific liquid chromatography-electrospray mass spectrometry, using an HPLC system (Agilent 1100 series, Agilent Technologies, CA, USA) equipped with a C18 cartridge (CAPCELL PAK C18 UG120A, Shiseido, Tokyo, Japan) and a mass spectrometer (Quattro Ultima, Micromass Technologies, Manchester, UK).

Serum HCV-RNA level was measured prior to treatment and at the final observation by a reverse transcriptional polymerase-chain-reaction method.

All analyses and measurements were performed in a single contract laboratory (SRL, Tokyo, Japan).

Statistical analysis
Patients' backgrounds were compared among the three dose groups by χ^2 test and ANOVA. Changes in serum ALT, AST and GGT levels due to UDCA administration were compared among the groups by repeated-measure ANOVA. Differences between groups were tested by using linear contrasts. Subgroup analyses of median changes in serum ALT at the final observation, relative to the pre-treatment levels, were performed according to gender, body weight and pre-treatment serum GGT level with Wilcoxon signed-ranks tests. Changes in bile acid and serum HCV-RNA levels were analysed by paired Student's t test. Fischer's exact probability test was applied to the incidences of adverse reactions. A p value <0.05 in a two-tailed test was considered significant. Analyses were done on the full analysis set. This study is registered at ClinicalTrial.gov, number NCT00200343, and is compliant with the published CONSORT guidelines for performance and publication of clinical trials.[12]

RESULTS
Patients
We enrolled 596 patients; 199 received UDCA at 150 mg/day, 200 at 600 mg/day, and 197 at 900 mg/day. Safety was evaluated in all patients as adverse events based on signs and symptoms and abnormal laboratory test results. Efficacy was evaluated in 586 patients (195, 150 mg/day; 198, 600 mg/day; and 193 at 900 mg/day), excluding 10 who lacked sufficient data. At the end of 24 weeks' administration, 392 patients were eligible for additional long-term administration. Of these patients, 280 chose to participate in the study and others refused mainly because of lack of time. Twenty three patients discontinued before week 52, one of them for biochemical relapse, and other 10 patients violated protocol. The effects of long-term administration were evaluated among the remaining 247 patients (fig 1).

Patients' backgrounds are summarised in table 1. Differences observed in gender, body weight and history of treatment with interferon between the three groups are indicated (p<0.15).

Changes in ALT, AST and GGT
Serum ALT, AST and GGT levels before and during treatment are shown in figs 2–4. The responses of ALT, AST and GGT over time were greater for 600 and 900 mg/day administration compared to 150 mg/day (ALT, p<0.001 and p=0.021; AST, p<0.001 and p<0.001; GGT, p<0.001 and p<0.001, respectively). No difference was observed between the 600 and 900 mg/day groups in ALT (p=0.926) or AST (p=0.429), but GGT differed significantly (p<0.001). Serum ALT, AST and GGT levels decreased by 4 weeks into treatment and remained

Figure 1 Trial profile.

constant. Serum ALT, AST and GGT levels at the final observation, together with median changes relative to 0 week (baseline), are shown in table 2. The mean decreases in serum ALT levels from the baseline value were 13.4, 30.6 and 29.3 IU/l in the 150, 600 and 900 mg/day groups, respectively. The median changes in ALT at the final observation were −15.3%, −29.2% and −36.2% in the corresponding groups (table 2).

The mean decreases in serum AST levels from the baseline value were 8.5, 19.3 and 19.7 IU/l in the 150, 600 and 900 mg/day groups, respectively. The mean decreases in serum GGT levels from the baseline value were 17.1, 32.7 and 42.1 IU/l in the 150, 600 and 900 mg/day groups, respectively.

Long-term effects
The decreases in ALT, AST, GGT levels from the baseline value were maintained during long-term administration of UDCA, as shown in table 3.

Subgroup analyses
The decrease in serum ALT was significantly greater in the 600 and 900 mg/day groups than in the 150 mg/day group for most subgroups by gender, body weight or baseline serum GGT levels (table 4). Although the difference between the 600 and 900 mg/day groups as a whole was not significant, the subgroup of baseline GGT⩾80 IU/l showed a significantly lower level of GGT with 900 mg/day administration (p = 0.004).

Bile acid in serum
Total bile acid concentration in serum increased in a dose-dependent manner from the start of drug administration to the final observation, as shown in table 5. The ratio of UDCA to total bile acid was increased significantly in all groups at the final observation compared to baseline. The ratio of UDCA at the final observation was similar in the 600 and 900 mg/day groups. The proportion of less hydrophilic bile acids was

Table 1 Characteristics of patients with chronic hepatitis C treated with UDCA (full analysis set)

	150 mg/day (n = 195)	600 mg/day (n = 198)	900 mg/day (n = 193)	p Value
Gender				
Male	97 (49.7%)	117 (59.1%)	123 (63.7%)	0.018
Female	98 (50.3%)	81 (40.9%)	70 (36.3%)	
Age (years)	58.0±12.2	57.7±12.0	59.8±10.1	0.152
Height (cm)	160.1±9.5	161.9±9.2	160.8±8.7	0.163
Weight (kg)	58.8±11.4	61.8±11.2	61.6±11.9	0.017
ALT (IU/l)	109.2±49.7	106.3±59.4	110.6±57.3	0.745
AST (IU/l)	84.0±39.1	82.4±41.8	85.2±45.0	0.796
GGT (IU/l)	87.5±73.0	82.4±62.2	85.9±66.3	0.744
Interferon*				
Absent	119 (61.0%)	100 (50.5%)	96 (49.7%)	0.044
Present	76 (39.0%)	98 (49.5%)	97 (50.3%)	

Data represent the number of patients or mean±SD.
*Previous interferon treatment.

Figure 2 Changes in serum ALT levels in patients with chronic hepatitis C before and during the treatment period. Data are expressed as mean ± SD. Open circles, 150 mg/day; filled circles, 600 mg/day; open triangles, 900 mg/day; *p<0.01, paired t test (vs week 0). The p values refer to repeated measures ANOVA.

decreased accordingly. The proportion of chenodeoxycholic acid at the final observation was decreased significantly in all groups, and was similar in the 600 and 900 mg/day groups. The proportions of cholic acid and deoxycholic acid were also decreased significantly compared to baseline.

Virus load

HCV-RNA levels (mean ± SD) changed from the baseline of 1477 ± 1280 to 1366 ± 1224 kIU/ml in the 150 mg/day group, from 1463 ± 1299 to 1358 ± 1233 kIU/ml in the 600 mg/day group, and from 1553 ± 1318 to 1552 ± 1398 kIU/ml in the 900 mg/day group. None of these changes was significant.

Figure 3 Changes in serum AST levels in patients with chronic hepatitis C before and during the treatment period. Data are expressed as mean ± SD. Open circles, 150 mg/day; filled circles, 600 mg/day; open triangles, 900 mg/day; *p<0.01, paired t test (vs week 0). The p values refer to repeated measures ANOVA.

Figure 4 Changes in serum GGT levels in patients with chronic hepatitis C before and during the treatment period. Data are expressed as mean ± SD. Open circles, 150 mg/day; filled circles, 600 mg/day; open triangles, 900 mg/day; *p<0.01, paired t test (vs week 0). The p values refer to repeated measures ANOVA.

Safety

The observed adverse reactions possibly associated with UDCA administration are shown in table 6. The overall incidences of adverse reactions were 18.1%, 21.5% and 17.8% in the 150, 600 and 900 mg/day groups, respectively, with no significant difference between the groups. Diarrhoea was reported most often. No severe adverse reactions were seen.

DISCUSSION

UDCA is frequently used for cholestatic liver diseases, primary biliary cirrhosis in particular. UDCA improves biochemical indices such as serum GGT, ALT and bilirubin. Histopathological improvements have been shown[13] and prolonged survival reported.[14][15] Although its effect on survival remains controversial,[16][17] UDCA is the only approved medication for primary biliary cirrhosis. Suggested mechanisms for UDCA include reducing the cytotoxicity of hydrophobic bile acids, stimulating hepatobiliary secretion and anti-apoptosis.[18]

UDCA was used to decrease serum aminotransferase levels for so-called non-A non-B chronic hepatitis before the discovery of HCV.[8][19][20] Takano et al restricted their study to patients with CH-C and found the optimal dose of UDCA to be 600 mg/day.[9] There was a greater reduction in GGT (40.5%) than in ALT (26.0%), as also observed in the current study. The reported effect of UDCA was stronger among CH-C patients with morphological bile duct injury,[21] and UDCA administration was accompanied by histological improvement of biliary lesions but not of hepatitis.[22] These data suggest that UDCA may act on the biliary system in CH-C through enhanced bile formation and/or modification of bile acid composition. In fact, bile duct injury is characteristic of CH-C, although not specific.[23] In this study, the changes in bile acid composition were similar in the 600 and 900 mg/day groups but smaller in the 150 mg/day group, and this may have been associated with the changes in serum biomarkers.

Nakamura et al reported that UDCA had a greater effect in CH-C patients with autoimmune characteristics, that is high immunoglobulin G concentration or positive anti-nuclear or anti-smooth muscle antibodies,[24] which suggests involvement

Table 2 Serum ALT, AST and GGT levels in patients with chronic hepatitis C after treatment with UDCA

	Dose (mg/day)	Pre-treatment, mean ± SD	Post-treatment, mean ± SD	Change (%), median (range)
ALT (IU/l)	150	109.2 ± 49.7	95.8 ± 60.2	−15.3 (−80.7 to +375.9)
	600	106.3 ± 59.4	75.7 ± 41.9	−29.2 (−88.3 to +95.2)
	900	110.6 ± 57.3	81.3 ± 90.5	−36.2 (−81.4 to +1696.9)
AST (IU/l)	150	84.0 ± 39.1	75.5 ± 43.6	−13.6 (−74.2 to +347.2)
	600	82.4 ± 41.8	63.1 ± 32.9	−25.0 (−82.7 to +72.5)
	900	85.2 ± 45.0	65.5 ± 49.6	−29.8 (−79.0 to +1026.1)
GGT (IU/l)	150	87.5 ± 73.0	70.4 ± 58.3	−22.4 (−74.6 to +145.9)
	600	82.4 ± 62.2	49.7 ± 43.0	−41.0 (−81.1 to +153.1)
	900	85.9 ± 66.3	43.8 ± 44.8	−50.0 (−80.1 to +213.9)

Table 3 Serum ALT, AST and GGT levels in patients with chronic hepatitis C during long-term administration of UDCA

	Pre-treatment	Treatment period		
	Week 0	Week 24	Week 48	Week 104
Patients (n)	247	242*	243†	149‡
ALT (IU/l)	114.8 ± 54.1	70.7 ± 37.4	67.9 ± 36.3	63.5 ± 31.9
AST (IU/l)	86.6 ± 41.7	59.0 ± 31.5	56.6 ± 27.4	54.1 ± 23.7
GGT (IU/l)	87.3 ± 67.6	49.5 ± 42.6	47.3 ± 40.5	41.8 ± 30.1

Data are expressed as mean ± SD.
*Corresponding data missing in five patients; †corresponding data missing in four patients; ‡administration between week 52 and week 104 was optional and 149 patients opted for the maximum term.

We examined the effect of UDCA on CH-C in terms of serum biochemical markers in a large-scale, double-blind investigation. We confirmed that a dose of 600 mg/day, that is 10 mg/kg body weight on average, was more effective than 150 mg/day, while adverse effects remained similar and minimal. The doses of 600 and 900 mg/day induced similar decreases in serum ALT and AST. Consequently, it appears that 600 mg/day is the preferred dose of UDCA, assuming that serum transaminase levels reflect the degree of hepatocellular damage.

The decrease in serum GGT differed significantly between the 600 and 900 mg/day groups. In contrast to the decrease in ALT or AST, that of serum GGT may represent improved cholestasis from biliary injury in CH-C. Although the importance of biliary injury in CH-C is unclear, it is possible that a 900 mg/day dose has additional benefits compared to 600 mg/day, as the incidence of adverse effects did not differ between the two doses. It is of interest that the decrease in ALT was significantly different between the two doses in patients with high baseline GGT levels (table 4).

The long-term effects of UDCA therapy in CH-C patients are yet to be elucidated. Changes in liver histology following UDCA administration are not evident from short-term observation. However, it is possible that delayed progression of fibrosis by UDCA can be revealed only by much longer-term observation,

of immunomodulatory mechanisms. Indeed, studies in vitro have shown that UDCA suppresses NF-κB-dependent transcription by binding to the glucocorticoid receptor[25] and decreases proinflammatory cytokine-induced transcription of phospholipase A2.[26] These mechanisms may act cytoprotectively in vivo. The choleretic and cytoprotective mechanisms are not necessarily mutually exclusive.

Table 4 Subgroup analyses of change in serum ALT in patients with chronic hepatitis C after treatment with UDCA

	Dose (mg/day)	No. of patients	Change (%), median (range)	p Value vs 150 mg	p Value vs 600 mg
Gender					
Male	150	97	−14.9 (−80.7 to +375.9)		
	600	117	−33.1 (−88.3 to +93.1)	<0.001	
	900	123	−36.4 (−79.1 to +1696.9)	<0.001	0.430
Female	150	98	−18.0 (−79.0 to +175)		
	600	81	−25.0 (−74.7 to +95.2)	0.058	
	900	70	−35.8 (−81.4 to +315.3)	0.002	0.076
Body weight (kg)					
<60	150	115	−14.9 (−80.7 to +375.9)		
	600	82	−28.6 (−74.7 to +95.2)	0.002	
	900	91	−35.2 (−81.4 to +315.3)	0.001	0.356
≥60	150	80	−16.7 (−73.4 to +166.1)		
	600	116	−30.3 (−88.3 to +93.1)	0.003	
	900	102	−36.6 (−77.1 to +1696.9)	<0.001	0.096
GGT (IU/l)					
≤39	150	45	−14.5 (−73.4 to +71.4)		
	600	39	−32.7 (−62.9 to +93.1)	0.049	
	900	45	−26.6 (−81.4 to +1696.9)	0.112	0.616
40–79	150	79	−15.2 (−69.1 to +175)		
	600	90	−30.3 (−74.7 to +95.2)	0.001	
	900	70	−36.3 (−77.7 to +200)	<0.001	0.633
≥80	150	71	−18.2 (−80.7 to +375.9)		
	600	69	−28.6 (−88.3 to +53.8)	0.057	
	900	78	−41.2 (−79.1 to +119.3)	<0.001	0.004

The p values refer to Wilcoxon signed-ranks tests.

Table 5 Composition of serum bile acid in patients with chronic hepatitis C treated with UDCA

	Dose (mg/day)	Before treatment	After treatment	p Value
Total bile acid concentration (μmol/l)	150	8.63±9.76	13.69±19.28	<0.001
	600	9.42±12.04	21.89±24.20	<0.001
	900	9.17±9.30	28.74±39.78	<0.001
Cholic acid (%)	150	17.69±10.33	11.35±7.08	<0.001
	600	17.75±10.35	5.93±4.53	<0.001
	900	18.15±9.54	5.14±4.19	<0.001
Deoxycholic acid (%)	150	21.62±16.24	13.84±11.39	<0.001
	600	19.86±16.84	6.50±7.06	<0.001
	900	18.74±15.29	5.68±6.58	<0.001
Chenodeoxycholic acid (%)	150	54.46±14.12	39.93±11.61	<0.001
	600	55.37±13.95	24.66±10.01	<0.001
	900	55.95±13.65	23.31±12.72	<0.001
Ursodeoxycholic acid (%)	150	5.93±8.72	34.25±13.75	<0.001
	600	6.70±9.72	62.26±13.69	<0.001
	900	6.83±10.6	65.12±16.84	<0.001
Lithocholic acid (%)	150	0.30±0.99	0.62±1.66	0.010
	600	0.33±1.23	0.66±1.35	0.010
	900	0.33±1.12	0.75±1.49	0.001

Data are expressed as mean±SD. The p values refer to paired t test (before vs after treatment).

because the natural progression of fibrosis in CH-C is usually slow, taking decades to establish cirrhosis.[27][28] The effect of UDCA lasted for at least 104 weeks without attenuation (table 3).

In the natural course of CH-C, those patients with normal serum aminotransferase levels show slow fibrosis progression[29] and a low incidence of hepatocellular carcinoma.[30][31] By multivariate analysis, the risk of hepatocellular carcinoma after interferon treatment without virological response was shown to be 0.26, 0.36 and 0.91 in patients whose ALT levels were normal, moderately elevated (less than twice the upper normal limit) and highly elevated, respectively, compared to untreated patients. It may be that when UDCA lowers serum ALT levels the risk of hepatocellular carcinoma is decreased. A retrospective study showed that hepatocellular carcinoma developed within 5 years from the onset of HCV-related early cirrhosis in 10 of 56 patients (18%) who took UDCA and 18 of 46 patients (39%) who did not.[32] Interestingly, ALT levels were similar in the two groups, possibly because UDCA was likely to be prescribed to those patients with high baseline ALT levels. Although these data were obtained from a non-randomised, retrospective study, they suggest that UDCA may provide cancer protective effects independent of decreasing ALT.

In summary, we confirmed, in a large-scale, double-blind study, that a UDCA dose of 600 mg/day was optimal to decrease serum ALT and AST levels in CH-C patients without serious adverse effects. A dose of 900 mg/day resulted in additional

decreases in serum GGT levels, and may be preferred in patients with prevailing biliary injuries. The long-term effects of UDCA administration on prognosis, hepatocarcinogenesis in particular, remain to be investigated in future studies.

ACKNOWLEDGEMENTS

Table 6 Summary of adverse reactions

	150 mg/day	600 mg/day	900 mg/day
Overall incidence	18.1% (36/199)	21.5% (43/200)	17.8% (35/197)
Total adverse reactions, n	44	62	45
Common adverse reactions, n (%)*			
Abdominal distension	2 (1.0)	2 (1.0)	2 (1.0)
Upper abdominal pain	2 (1.0)	4 (2.0)	2 (1.0)
Constipation	3 (1.5)	4 (2.0)	2 (1.0)
Diarrhoea	7 (3.5)	8 (4.0)	8 (4.1)
Dyspepsia	3 (1.5)	2 (1.0)	2 (1.0)
Loose stool	1 (0.5)	6 (3.0)	5 (2.5)
Stomach discomfort	2 (1.0)	2 (1.0)	3 (1.5)
Pruritus	3 (1.5)	3 (1.5)	2 (1.0)

*The adverse reactions which were observed in 1% or more of the patients.

Authors' affiliations
Masao Omata, Haruhiko Yoshida, Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Joji Toyota, Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan
Eiichi Tomita, Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan
Shuhei Nishiguchi, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
Norio Hayashi, Department of Molecular Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan
Shiro Iino, Seizankai Kiyokawa Hospital, Tokyo, Japan
Isao Makino, Hokushinkai Megumino Hospitals, Hokkaido, Japan
Kiwamu Okita, Social Insurance Shimonoseki Kosei Hospital, Yamaguchi, Japan
Gotaro Toda, Sempo Tokyo Takanawa Hospital, Tokyo, Japan
Kyuichi Tanikawa, International Institute for Liver Research, Fukuoka, Japan
Hiromitsu Kumada, Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan

REFERENCES
1 Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis* 2000;**20**:1–16.
2 El-Serag HB, Davila JA, Petersen NJ, *et al.* The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann Intern Med* 2003;**139**:817–23.
3 Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. *Oncology* 2002;**62**(Suppl 1):8–17.
4 Manns MP, McHutchison JG, Gordon SC, *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;**358**:958–65.
5 Fried MW, Shiffman ML, Reddy KR, *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;**347**:975–82.
6 Poupon R, Chretien Y, Poupon RE, *et al.* Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? *Lancet* 1987;**1**:834–6.
7 Leuschner U, Fischer H, Kurtz W, *et al.* Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. *Gastroenterology* 1989;**97**:1268–74.
8 Leuschner U, Leuschner M, Sieratzki J, *et al.* Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. *Dig Dis Sci* 1985;**30**:642–9.
9 Takano S, Ito Y, Yokosuka O, *et al.* A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. *Hepatology* 1994;**20**:558–64.
10 Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;**36**:S47–S56.
11 Ghany MG, Kleiner DE, Alter H, *et al.* Progression of fibrosis in chronic hepatitis C. *Gastroenterology* 2003;**124**:97–104.
12 Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;**357**:1191–4.
13 Degott C, Zafrani ES, Callard P, *et al.* Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. *Hepatology* 1999;**29**:1007–12.
14 Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. *N Engl J Med* 1994;**330**:1342–7.
15 Lindor KD, Therneau TM, Jorgensen RA, *et al.* Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. *Gastroenterology* 1996;**110**:1515–18.
16 Poupon RE, Lindor KD, Cauch-Dudek K, *et al.* Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. *Gastroenterology* 1997;**113**:884–90.
17 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. *Lancet* 1999;**354**:1053–60.
18 Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. *Hepatology* 2002;**36**:525–31.
19 Osuga T, Tanaka N, Matsuzaki Y, *et al.* Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. *Dig Dis Sci* 1989;**34**(12 Suppl):49S–51S.
20 Podda M, Ghezzi C, Battezzati PM, *et al.* Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. *Gastroenterology* 1990;**98**:1044–50.
21 Kiso S, Kawata S, Imai Y, *et al.* Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. *J Gastroenterol* 1996;**31**:75–80.
22 Attili AF, Rusticali A, Varriale M, *et al.* The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. *J Hepatol* 1994;**20**:315–20.
23 Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. *Semin Liver Dis* 1995;**15**:70–81.
24 Nakamura K, Yoneda M, Takamoto S, *et al.* Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. *J Gastroenterol Hepatol* 1999;**14**:413–18.
25 Miura T, Ouchida R, Yoshikawa N, *et al.* Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. *J Biol Chem* 2001;**276**:47371–8.
26 Ikegami T, Matsuzaki Y, Fukushima S, *et al.* Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. *Hepatology* 2005;**41**:896–905.
27 Poynard T, Bedossa P, Opolon P, OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 1997;**349**:825–32.
28 Shiratori Y, Imazeki F, Moriyama M, *et al.* Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 2000;**132**:517–24.
29 Mathurin P, Moussalli J, Cadranel JF, *et al.* Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *Hepatology* 1998;**27**:868–72.
30 Yoshida H, Shiratori Y, Moriyama M, *et al.* IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med* 1999;**131**:174–81.
31 Tarao K, Rino Y, Ohkawa S, *et al.* Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A. *Intervirology* 2004;**47**:65–71.
32 Tarao K, Fujiyama S, Ohkawa S, *et al.* Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. *Cancer Epidemiol Biomarkers Prev* 2005;**14**:164–9.

BASIC STUDIES

New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle

Miharu Hirakawa, Kenji Ikeda, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase and Hiromitsu Kumada

Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Abstract
Objective: The stepwise hook extension technique for an expandable needle, which we reported previously, allowed roll-off in short time with low power. The aim of this study was to investigate experimentally the efficacy of a modified extension procedure. *Methods:* Three pigs underwent 10 radiofrequency ablation (RFA) procedures using the 10-hook electrode of LeVeen needle. The conventional technique was used in five RFA (group 1; the electrode was deployed in four steps to full extension), while the new technique was used in the other five RFA (group 2; the electrode was closed after the same three steps as group 1 and then fully extended). *Results:* The shape of the RFA-induced zone was cone-like or irregular in group 1 and oval-like in group 2. The diameter vertical to the shaft was larger in group 2 (37, range 33–42 mm) than in group 1 (23, range 20–29 mm). The median ablation time was longer in group 2 (10 min 13 s) than in group 1 (3 min 56 s). Although the required energy was higher in group 2 than in group 1, that per volume was comparable between the groups (median 0.9 vs. 1.4 kJ/mm^3). *Conclusions:* Our new procedure requires a longer session but produces larger necrosis of a uniform ellipsoid volume, making it potentially suitable for tumours more than 3 cm in diameter.

Percutaneous treatment including radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) is often used for small-size hepatocellular carcinoma (HCC) as it is less invasive than surgical therapy. RFA has become the first-choice local treatment because of the excellent outcome; the efficacy of RFA in HCC tumours measuring < 2 cm in diameter is similar to that of PEI but it requires fewer treatment sessions, and the efficacy in HCC tumours > 2 cm in diameter is better than with PEI (1). In addition, RFA is also more cost-effective than surgical resection of small HCC (2). Because the volume ablated during one RFA session is of a diameter < 3.0–4.0 cm in most cases, RFA therapy is now restricted to tumour < 3 cm. In this regard, previous studies reported that the necrotic area could be enlarged by a saline injection before RFA (3, 4), combination of RFA with PEI (5, 6), RFA with an ethanol–lipiodol injection (7), RFA with transcatheter arterial embolization (8) and RFA with transient arterial obliteration (9–11).

Among the three commercially available RFA apparatuses, the radiofrequency tumour coagulation system (RTC system; Boston Scientific, Natick, MA, USA), radiofrequency interstitial tumour ablation system (RITA System, RITA Medical Systems Inc., Mountain View, CA, USA) and cool-tip RF system (Radionics Inc., Burlington, VT, USA), the first two types have adopted the expandable needle. We reported previously the efficacy of the stepwise hook extension technique for RFA therapy of HCC (12). The technique allows rapid roll-off at a lower power and reduces any possible increase in intratissue pressure that may cause scattering of intrahepatic metastasis (13–15). Additionally, we have designed a new technique involving full re-expansion after stepwise extension, that may ensure full expansion of the needle to enlarge the ablated zone. The aim of this study was to investigate experimentally the new expansion technique and to compare it with the conventional stepwise extension technique.

Materials and methods

We used the RTC system comprising the RF3000 generator and a slim expandable needle (30 mm,

Fig. 2. The new stepwise procedure. (A) A quarter-length of the electrode tines is expanded in the first step. (B) A half-length is expanded in the second step. (C) A three-quarter length is expanded in the third step. (D) The electrode tines are closed in the shaft. (E) Tines are expanded to full length in the final step.

Table 1. Duration of ablation (in minutes seconds) and RF-induced area in groups 1 and 2

	Group 1					Group 2				
	1	2	3	4	5	1	2	3	4	5
Duration										
First step	2' 55"	3' 00"	1' 18"	1' 24"	0' 58"	1' 47"	2' 15"	2' 46"	1' 42"	1' 10"
Second step	2' 14"	1' 28"	0' 49"	0' 27"	0' 32"	1' 02"	2' 33"	0' 18"	0' 17"	0' 23"
Third step	0' 58"	1' 40"	0' 35"	0' 45"	0' 34"	1' 48"	1' 01"	1' 26"	0' 22"	0' 32"
Fourth step	0' 44"	2' 28"	1' 14"	0' 56"	0' 52"	5' 36"	6' 40"	6' 19"	6' 29"	4' 29"
Total	6' 51"	8' 36"	3' 56"	3' 32"	2' 56"	10' 13"	12' 29"	10' 49"	8' 50"	6' 34"
RF-induced area										
Transverse diameter, mm	20	28	25	23	22	33	42	38	37	35
Longitudinal length, mm	27	24	30	30	32	20	30	27	27	34
Shape	Irregular	Cone-like	Cone-like	Cone-like	Cone-like	Ellipsoid	Ellipsoid	Ellipsoid	Ellipsoid	Ellipsoid

larger in group 2 than that in group 1 (group 1: 5.5 kJ range 4.0–14.8 kJ, group 2: 25.0 kJ range 13.4–30.6 kJ, $P = 0.016$) respectively.

Size and shape of ablated tissue

Table 1 shows the shape and size of the RF-induced areas in groups 1 and 2. In group 1, the shape of the ablated zone was cone-like or was sometimes irregu-

larly shaped. The length along the shaft was longer than the vertical diameter as shown in Figure 3A. In group 2, the ablated zone was near-oval in shape, with the short axis equivalent to the shaft (Fig. 3B). As shown in Table 2, the area perpendicular to the shaft and the ablation volume were larger in group 2 than in group 1: vertical diameter: 23 (range 20–28) mm vs. 37 (range 33–42) mm ($P = 0.008$). This indicates that our technique produced a larger area of necrosis following

Fig. 2. The new stepwise procedure. (A) A quarter-length of the electrode tines is expanded in the first step. (B) A half-length is expanded in the second step. (C) A three-quarter length is expanded in the third step. (D) The electrode tines are closed in the shaft. (E) Tines are expanded to full length in the final step.

**Table 1.** Duration of ablation (in minutes seconds) and RF-induced area in groups 1 and 2

	Group 1					Group 2				
	1	2	3	4	5	1	2	3	4	5
Duration										
First step	2' 55"	3' 00"	1' 18"	1' 24"	0' 58"	1' 47"	2' 15"	2' 46"	1' 42"	1' 10"
Second step	2' 14"	1' 28"	0' 49"	0' 27"	0' 32"	1' 02"	2' 33"	0' 18"	0' 17"	0' 23"
Third step	0' 58"	1' 40"	0' 35"	0' 45"	0' 34"	1' 48"	1' 01"	1' 26"	0' 22"	0' 32"
Fourth step	0' 44"	2' 28"	1' 14"	0' 56"	0' 52"	5' 36"	6' 40"	6' 19"	6' 29"	4' 29"
Total	6' 51"	8' 36"	3' 56"	3' 32"	2' 56"	10' 13"	12' 29"	10' 49"	8' 50"	6' 34"
RF-induced area										
Transverse diameter, mm	20	28	25	23	22	33	42	38	37	35
Longitudinal length, mm	27	24	30	30	32	20	30	27	27	34
Shape	Irregular	Cone-like	Cone-like	Cone-like	Cone-like	Ellipsoid	Ellipsoid	Ellipsoid	Ellipsoid	Ellipsoid

larger in group 2 than that in group 1 (group 1: 5.5 kJ range 4.0–14.8 kJ, group 2: 25.0 kJ range 13.4–30.6 kJ, $P = 0.016$) respectively.

Size and shape of ablated tissue

Table 1 shows the shape and size of the RF-induced areas in groups 1 and 2. In group 1, the shape of the ablated zone was cone-like or was sometimes irregu-

larly shaped. The length along the shaft was longer than the vertical diameter as shown in Figure 3A. In group 2, the ablated zone was near-oval in shape, with the short axis equivalent to the shaft (Fig. 3B). As shown in Table 2, the area perpendicular to the shaft and the ablation volume were larger in group 2 than in group 1: vertical diameter: 23 (range 20–28) mm vs. 37 (range 33–42) mm ($P = 0.008$). This indicates that our technique produced a larger area of necrosis following

Table 2. Comparison of ablation time (in minutes seconds) and RF-induced areas between groups 1 and 2

	Group 1	Group 2	P
Incidence of roll-off	5/5	5/5	1.000
Duration of the first step	1′ 24″ (0′ 58″–3′ 00″)	1′ 47″ (1′ 10″–2′ 46″)	1.000
Second step	49″ (0′ 27″–2′ 14″)	23″ (17″–2′ 33″)	0.421
Third step	45″ (0′ 34″–1′ 40″)	1′ 1″ (22″–1′ 48″)	1.000
Fourth step	56″ (0′ 44″–2′ 28″)	6′ 19″ (4′ 29″–6′ 40″)	0.008
Total ablation time	3′ 56″ (2′ 56″–8′ 36″)	10′ 13″ (6′ 34″–12′ 29″)	0.032
Required energy for ablation, kJ	5.5 (4.0–14.8)	25.0 (13.4–30.6)	0.016
Diameter of the cross-section vertical to the axis, mm	23 (20–28)	37 (33–42)	0.008
Axial length, mm	30 (24–32)	27 (20–34)	0.841
Shape of RF-induced area			
Ellipsoid	0	5	
Cone-like	4	0	
Irregular	1	0	

Fig. 3. Photographs of the coagulated area. Arrow shows the direction of the needle shaft. (A) The shape of the area produced by the conventional procedure is cone-like (RFA#3). (B) The shape of the area produced by the new procedure is ellipsoid in shape (RFA#3).

one session of RF. Although the axial length of the ablation zone showed no significant difference between the two groups, that in group 2 seemed a slightly shorter than that in group 1: axial length: 30 (range 24–32) mm vs. 27 (range 20–34) mm ($P = 0.841$). Based on the assumption that the shape of the necrotic area was a combination of a hemisphere and a cone in group 1 and an ellipsoid in group 2, the estimated volume of the ablated liver tissue was 5.7 (range 3.8–7.8) μm^3 for group 1 and 20 (range 11–28) μm^3 for group 2. Using this value and the total required energy for ablation, the calculated energy required for ablation per volume was 0.9 (range 0.7–2.5) J/mm^3 for group 1 and 1.4 (range 0.6–1.8) J/mm^3 for group 2 ($P = 1.000$).

Needle expansion

Figures 4 and 5 show X-ray images of the electrode tines in the pig liver at each step. Both in the second step and the third step, the progress of the tines' spread was smaller than at the first step. The needle expansion at the third step did not reach three quarters length in both groups 1 and 2. The extent of the expansion at the final step was nearly similar to that at the second and third steps in group 1, while it was nearly complete in group 2.

Discussion

Radiofrequency ablation therapy is one of the curative therapies for HCC measuring < 30 mm in diameter, while surgical resection is the only curative treatment for HCC more than 30 mm and < 50 mm in diameter. However, surgical resection cannot be performed in patients with cirrhotic liver and liver dysfunction. Thus, a technique that widens the RF-ablated area can improve, at least theoretically, the survival of cirrhotic patients with HCC over 30 mm in diameter.

Fig. 4. Electrode tines in a pig liver during the conventional four-stepwise extension procedure. (A) First step. (B) Second step. (C) Third step. (D) Final step. At the second step, the third step and the final step, the progress of the tines' spread is smaller in comparison with that at the first step. The extent of the expansion at the final step was nearly similar to that at the second and third steps.

Fig. 5. Electrode tines in a pig liver during the new stepwise extension procedure. (A) First step. (B) Second step. (C) Third step. (D) Final step. At the second step, the third step and the final step, the progress of the tines' spread is smaller in comparison with that at the first step. The extent of the expansion at the final step was nearly complete.

The shape of the ablated zone depends on the needle type (6). For example, the path along the shaft is longer than the transverse diameter when using the cool-tip electrode (Radionics System; Radionics, Burlington, VT, USA), shorter when using the expandable needle of RTC system and compatible with each other when using the LeVeen needle (RTC system). The shorter path is less disadvantageous than the shorter perpendicular diameter, because the ablated zone along with the needle trace can be enlarged by repeating the procedure as the needle is extracted while that perpendicular to the tract cannot be enlarged during one insertion. Although it is often difficult to achieve roll-off during a single-step full expansion procedure using the LeVeen needle, our stepwise procedure has overcome this difficulty and produced an oval ablation zone similar to the single-step procedure.

The LeVeen needle, which had a diameter of 14 G in the first stage, has been made slender for the ease and safety of insertion into the liver. The needle now available in the market has a diameter of 17 G. The slim needle may be easier to deform during insertion and difficult to fully extend within the liver by the

conventional stepwise method. The liver tissue resistance consists of resistance acting on the needle tip and that on the side. The strength of the former is proportional to the cross-section and that of the latter is to the surface area. Based on this, the slender shaft is subjected to a large stress and strain resulting in larger deformation, although its resistance is smaller. Thus, the hooks of the slim needle hardly extend as expected; it cannot be fully extended when expanded slowly as shown in Figure 4. This is because the shaft is pushed back as the electrode is inserted towards the liver. To overcome this inconvenience, we investigated a new technique: full re-expansion after stepwise extension, which allows a sharper and definite expansion of the slim needle to full length. Thus, this technique is suggested to be more advantageous in a slimmer needle; this procedure has not been examined in needles 14 or 15 G in diameter.

The additional reason for the larger ablation zone made by the new method is that the tanned tumour or parenchymal tissue would be removed from the surface of the multiple tines when they are once closed in the shaft. The tan was observed on the tip of the shaft

when the needle was extracted from the liver. The tan adhering on the tine may prevent the uniform electric current, which results in a decrease in the electric efficiency. Thus, the removal of tan can result in an increase in the effectiveness of RF ablation procedure and that in the ablation zone.

A larger ablation zone at the final step of the new technique required a longer coagulation time and a higher input energy during the final step and during the total session; the ablation zone, ablation time and the required energy by our method were larger than those by the conventional stepwise method. The required energy per volume, on the other hand, was almost identical.

In conclusion, the new extension procedure for the expandable needle allows coagulation of larger and more oval area even when using the slim needle. This method may be useful to expand the application of RFA for hepatic tumours.

References

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208–36.
2. Ikeda K, Kobayashi M, Saitoh S, *et al.* Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. *Hepatol Res* 2005; **33**: 241–9.
3. Livraghi T, Goldberg SN, Monti F, *et al.* Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastasis. *Radiology* 1997; **202**: 205–10.
4. Burdio F, Guemes A, Burdio JM, *et al.* Large hepatic ablation with bipolar saline-enhanced radiofrequency: an experimental study *in vivo* porcine liver with a novel approach. *J Surg Res* 2003; **110**: 193–201.
5. Kurokohchi K, Watanabe S, Masaki T, *et al.* Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocellular carcinoma. *Intern J Oncol* 2002; **21**: 841–6.
6. Watanabe S, Kurokohchi K, Masaki T, *et al.* Enlargement of thermal ablation zone by the combination of ethanol injection and radiofrequency ablation in excised bovine liver. *Intern J Oncol* 2004; **24**: 279–84.
7. Kurokohchi K, Masaki T, Miyauchi Y, *et al.* Efficacy of combination therapies of percutaneous on laparoscopic ethanol–lipiodol injection and radiofrequency ablation. *Intern J Oncol* 2004; **25**: 1737–43.
8. Sugimori K, Morimoto M, Shirato K, *et al.* Radiofrequency ablation in a pig liver model: effect of transcatheter arterial embolization on coagulation diameter and histological characteristics. *Hepatol Res* 2002; **24**: 164–73.
9. Yamasaki T, Kurosawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. *Cancer* 2001; **91**: 1342–8.
10. Kobayashi M, Ikeda K, Kawamura Y, *et al.* Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome. *Liver Int* 2007; **27**: 353–9.
11. Chinn SB, Lee FT Jr., Kennedy GD, *et al.* Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. *Am J Roentgenol* 2001; **176**: 789–95.
12. Kobayashi M, Ikeda K, Someya T, *et al.* Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma. *Oncology* 2002; **63**: 139–44.
13. Nakamuta M, Kohjima M, Morizono S, *et al.* Comparison of tissue pressure and ablation time between LeVeen and cool-tip needle methods. *Comp Hepatol* 2006; **5**: 10.
14. Kotoh K, Nakamuta M, Morizono M, *et al.* A multi-step, incremental expansion method for radio frequency ablation: optimization of the procedure to prevent increases in intra-tumor pressure and to reduce the ablation time. *Liver Int* 2005; **25**: 542–7.
15. Kotoh K, Enjoji M, Arimura E, *et al.* Scattered and rapid intrahepatic recurrences after radio frequency ablation for hepatocellular carcinoma. *World J Gastroenterol* 2005; **11**: 6828–32.

Original Article

Diabetes mellitus reduces the therapeutic effectiveness of interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C

Ichiro Konishi,[1,2] Norio Horiike,[1] Yoichi Hiasa,[1] Yoshio Tokumoto,[1] Toshie Mashiba,[1] Kojiro Michitaka,[3] Yasuyuki Miyake,[4] Suguru Nonaka,[4] Kouji Joukou,[5] Bunzo Matsuura[1] and Morikazu Onji[1]

[1]*Department of Gastroenterology and Metabology,* [2]*Department of Basic Medical Research and Education, and* [3]*Endoscopy Center, Ehime University Graduate School of Medicine, Shitsukawa, Toon,* [4]*Department of Internal Medicine, Ehime Prefectural Imabari Hospital, Imabari, and* [5]*Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan*

Aim: Patients with chronic hepatitis C (CHC) often have diabetes mellitus (DM). However, it is unknown whether DM affects patient response to interferon (IFN) plus ribavirin therapy. Therefore, the aim of this study was to examine the influence of DM on the outcome of IFN-α2b plus ribavirin therapy.

Methods: In a cohort of 110 patients with CHC, the outcome of 6 months of IFN-α2b plus ribavirin therapy was evaluated by comparing the patients with and without DM.

Results: There were 46 sustained-responders; 64 patients did not become sustained responders. Higher age ($P = 0.015$), lower platelet counts ($P = 0.036$), hepatitis C virus (HCV) serotype 1 ($P = 0.001$), advanced liver fibrosis ($P = 0.004$), and the presence of DM ($P = 0.007$) were significantly associated with not becoming a sustained-responder. Seventeen CHC

(15%) patients had DM. Sex ratio, age, body mass index, alanine aminotransferase levels, HCV-RNA titer, and HCV serotypes did not significantly differ between the patients with and without DM, while fasting plasma glucose, hemoglobin A1c and liver histological staging were significantly different. On multiple logistic regression analysis, HCV serotype 1 (odds ratio 8.743, 95% confidence interval 2.215–34.517; $P = 0.002$) and the presence of DM (odds ratio 8.657, 95% confidence interval 1.462–51.276; $P = 0.014$) were independently associated with not becoming a sustained-responder.

Conclusions: The findings indicate that DM reduces the response to IFN-α2b plus ribavirin therapy in CHC patients.

Key words: chronic hepatitis C, diabetes mellitus, interferon, ribavirin

INTRODUCTION

CHRONIC HEPATITIS C (CHC) has a high prevalence worldwide. Over a period of 20–30 years, CHC progresses to cirrhosis and hepatocellular carcinoma.[1] Interferon (IFN) is often administered to treat chronic hepatitis C virus (HCV) infection, yet many patients do not eliminate the virus. Recently, therapy with IFN combined with ribavirin has been given to patients with a high viral load or who relapse; compared to IFN monotherapy, combination therapy increases the

Correspondence: Morikazu Onji MD, Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa Toon Ehime 791-0295, Japan.
Email: onjimori@m.ehime-u.ac.jp

rate of sustained viral response (SVR).[2,3] However, the rate of SVR is still not high enough.

Several factors that contribute to the response to IFN therapy have been identified. A high viral load, viral genotype 1b, and the absence of mutations in the NS5A and NS5B regions in genotype 1b of HCV are associated with a lower rate of HCV clearance in patients receiving antiviral therapy.[4–7] Host factors, including older age, a higher degree of fibrosis, a longer duration of disease, and certain host genetic factors that affect IFN responsiveness, are associated with a poor response to IFN therapy.[8–14] Furthermore, in previous studies, most patients who received combination IFN-α2b plus ribavirin therapy had a high HCV viral load and were serotype 1; thus, there may be other factors that reduce the efficacy of IFN-α2b plus ribavirin therapy.

Diabetes mellitus (DM) has been associated with HCV infection, especially in patients with liver

331

cirrhosis.[15] Furthermore, DM has been implicated in insulin resistance and obesity, which affect IFN effectiveness.[16–18] However, there is no evidence that DM affects the outcome of IFN-α2b plus ribavirin therapy. Therefore, we explored whether the presence of DM affects the response to IFN-α2b plus ribavirin therapy in patients with CHC.

METHODS

Patients

WE ENROLLED 110 CHC patients (male, 86; female, 24; median age, 51 years; range, 27–74 years) who were given IFN-α2b plus ribavirin therapy from December 2001 to August 2003 at our hospital. All participants were Japanese and unrelated to each other. All patients were positive for both anti-HCV antibody and serum HCV-RNA by polymerase chain reaction (PCR). Ninety-two of the patients had HCV serotype 1, and 18 had HCV serotype 2. The patients were separated based on their viral load determined by the Amplicor-Monitor assay into three groups: more than 700 KIU/mL ($n = 66$); 100–700 KIU/mL ($n = 41$); and less than 100 KIU/mL ($n = 3$). No patients had hepatitis B virus (HBV) infection, alcohol-induced liver diseases, or autoimmune liver diseases. Sixty-two patients had received prior antiviral treatment, while 48 patients had not.

Patients were classified as having DM according to criteria for the diagnosis of type 2 DM established in 1999 by the Japan Diabetes Society, which are similar to the WHO type 2 DM diagnostic criteria. In 46 patients, we evaluated glucose intolerance and insulin resistance using 75-g oral glucose tolerance test.

Liver biopsy specimens were obtained from 108 patients for histological examination: 39 had mild fibrosis; 34 had moderate fibrosis; 23 had severe fibrosis; and 12 had liver cirrhosis. Histological activity was mild in 51, moderate in 56, and severe in one. Specimens were histologically classified according to the criteria of the International Hepatitis Group.[19]

Informed consent was obtained from all patients.

Estimation of HBV and HCV markers and laboratory investigations

The presence of hepatitis B surface antigen (HBsAg) and anti-HCV antibody was determined using enzyme immunoassay kits (Dainabot, Tokyo, Japan; Kokusai-Shiyaku, Kobe, Japan). HCV-RNA was detected using the nested PCR with primers for the 5′ untranslated region of HCV. The HCV-RNA titers immediately before IFN-α2b plus ribavirin therapy that were determined using Amplicor-Monitor (Roche Diagnostics, Branchburg, NJ, USA) are expressed as kilo-international units/mL (KIU/mL).[20] The HCV serotype was determined using an enzyme immunoassay (Ohtsuka Laboratories, Tokushima, Japan). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as reported previously.[21]

Treatment schedule

All patients were treated with combination recombinant IFN-α2b and ribavirin therapy at the Ehime University Hospital from December 2001 to August 2003. Ribavirin (Schering-Plough, Osaka, Japan) was given at a daily dose of 600 or 800 mg, depending on body weight (<60 or ≥60 kg, respectively), in combination with IFN-α2b (Schering-Plough) intramuscularly every day for the first 1–4 weeks, and then three times a week for the following 20–23 weeks (total duration, 24 weeks). The starting doses of IFN-α2b were 10 MU per day in 104 patients and 6 MU per day in six patients. Ribavirin was started at 800 mg per day in 72 patients and 600 mg per day in 38 patients.

During treatment, the IFN dose was decreased in 19 patients (17%), and both IFN and ribavirin were discontinued in 17 patients (15%) due to side-effects; the ribavirin dose was decreased in 35 patients (32%), and ribavirin was discontinued without stopping IFN in three patients. Fifty-five patients (50%) completed treatment without discontinuing or decreasing the dosage of either drug.

Criteria for IFN effectiveness

All patients were followed for at least 6 months after IFN-α2b plus ribavirin therapy. Serum alanine aminotransferase (ALT) and HCV-RNA were assayed monthly during this period. Patients were categorized into two groups. Patients with an SVR (sustained-responders) were those who maintained normal ALT levels and had no detectable HCV-RNA based on PCR assays done during the follow-up period; non-responders were those patients who remained positive for HCV-RNA after IFN-α2b plus ribavirin therapy, irrespective of the HCV-RNA levels or the occurrence of relapse during follow-up.

Statistical analysis

All data are expressed as the medians. For continuous variables, the Mann–Whitney *U*-test was used. The difference in proportions was evaluated using the chi-squared test or Fisher's exact test. We assessed all

variables using a logistic regression model. The model was simplified in a stepwise fashion by removing variables with $P > 0.05$. A value of $P < 0.05$ was considered significant. Calculations were performed using SPSS for Windows, Release 14.0 J (SPSS, Chicago, IL, USA).

RESULTS

Clinical and virological characteristics according to IFN response

FORTY-SIX PATIENTS (42%) were sustained-responders, and 64 (58%) were non-responders. The characteristics of the sustained-responders and the non-responders are shown in Table 1. Sex ratio, body mass index, fasting plasma glucose, hemoglobin (HbA1c), ALT levels, HCV-RNA titer, liver histological activity, and past history of IFN therapy were not significantly different between sustained-responders and non-responders. However, the following were significantly associated with non-response: older age ($P = 0.015$), lower platelet

count ($P = 0.036$), HCV serotype 1 ($P = 0.001$), advanced fibrosis ($P = 0.004$), and the presence of DM ($P = 0.007$).

Of the 48 patients identified with fasting plasma glucose and immunoreactive insulin levels, the HOMA-IR was not significantly different between the sustained-responders ($n = 18$; median 2.63, range 0.8–13.3) and the non-responders ($n = 28$; median 2.99, range 0.6–9.5).

Background characteristics of patients with and without DM

To assess the influence of DM, we compared the clinical and virological features of patients with and without DM (Table 2). No patient with DM received drugs that improve insulin resistance. Sex ratio, age, body mass index, ALT levels, liver histological staging, HCV-RNA titer, HCV serotypes, and past history of IFN therapy were not statistically significantly different between the two groups. However, fasting plasma glucose and

Table 1 Clinical and virological characteristics of 110 patients with chronic hepatitis C treated with interferon-α2b plus ribavirin therapy based on therapeutic response

Characteristic	Sustained-responders ($n = 46$)	Non-responders ($n = 64$)	P-value
Sex (male/female)	35/11	51/13	NS
Age (years)	46 (32–65)	54 (27–74)	0.015
Body mass index (kg/m²)	24.1 (17.7–31.7)	23.6 (16.6–32.4)	NS
Fastening plasma glucose (mg/dL)	92 (69–140)	96 (73–209)	NS
HbA1c (%)	4.9 (4.2–6.3)	5.0 (4.2–8.7)	NS
Alanine aminotransferase (IU/L)	68 (20–337)	72 (25–247)	NS
Platelet count (×10⁴/mm²)	16.7 (6.4–35.3)	15.0 (5–32.2)	0.036
HCV serotype			
1	32	60	0.001
2	14	4	
HCV-RNA titer			
<100 KIU/mL	3	0	NS
100–700 KIU/mL	19	22	
>700 KIU/mL	24	42	
Histological fibrosis			
Mild	23	16	0.004
Moderate	8	26	
Severe	12	11	
Cirrhosis	2	10	
Histological activity			
Mild	21	30	NS
Moderate	24	32	
Severe	0	1	
Re-treatment (+/−)	26/20	36/28	NS
Presence of DM (non-DM/DM)	44/2	49/15	0.007

Data expressed as median (range). DM, diabetes mellitus; HbA1c, hemoglobin A1c; HCV, hepatitis C virus; NS, not significant.

© 2007 The Japan Society of Hepatology

Table 2 Clinical and virological characteristics of 110 patients with chronic hepatitis C treated with interferon-α2b plus ribavirin therapy based on the presence of diabetes mellitus

Characteristic	Patients with DM (n = 17)	Patients without DM (n = 93)	P-value
Sex (male/female)	15/2	71/22	NS
Age (years)	55 (39-74)	49 (27-69)	NS
Body mass index (kg/m²)	23.5 (17.5-32.4)	24.0 (16.6-31.7)	NS
Fastening plasma glucose (mg/dL)	109 (93-209)	92 (69-110)	<0.001
HbA1c (%)	6.7 (5.0-8.7)	4.9 (4.2-5.8)	<0.001
Alanine aminotransferase (IU/L)	93 (39-234)	68 (20-337)	NS
Platelet count (×10⁴/mm²)	14.8 (7.8-32.2)	15.9 (5-35.3)	NS
HCV serotype			
1	14	78	NS
2	3	15	
HCV-RNA titer			
<100 KIU/mL	0	3	NS
100-700 KIU/mL	4	37	
>700 KIU/mL	13	53	
Histological fibrosis			
Mild	3	36	NS
Moderate	4	30	
Severe	6	17	
Cirrhosis	3	9	
Histological activity			
Mild	8	43	NS
Moderate	8	48	
Severe	0	1	
Re-treatment (+/-)	9/8	53/40	NS

Data expressed as median (range). DM, diabetes mellitus; HbA1c, hemoglobin A1c; HCV, hepatitis C virus; NS, not significant.

HbA1c were significantly higher in patients with DM than in those without DM (both $P < 0.001$). Furthermore, SVR was achieved in no patients with an HbA1c ≥6.9%, but was achieved in 11% of patients with an HbA1c <6.9% ($P < 0.05$). The rate of discontinuation of IFN-α2b plus ribavirin therapy due to side-effects did not differ between patients with DM (3/17, 18%) and those without DM (11/93, 12%).

Multiple logistic regression analysis of the factors affecting therapeutic outcome

To evaluate the significance of variables with respect to the outcome of IFN-α2b plus ribavirin therapy, a logistic model to assess factors related to SVR was constructed using all of the variables. The model was refined until it included only the variables independently associated with non-response (Table 3). The two variables were HCV serotype 1 (odds ratio 8.743; 95% confidence interval 2.215-34.517; $P = 0.002$) and the presence of DM (odds ratio 8.657; 95% confidence interval 1.462-51.276; $P = 0.014$).

DISCUSSION

THE PRESENT STUDY offers evidence that DM is one of the independent factors that reduces the effect of 6-month IFN-α2b plus ribavirin therapy in CHC patients. The prevalence of DM is 13-27.6% of CHC patients.[22-26] In some studies, DM patients were shown to have more advanced liver fibrosis than patients without DM,[24,25] and advanced liver fibrosis is a factor

Table 3 Multivariate analysis of the effect of variables on the response to interferon-α2b plus ribavirin therapy

Variable	P-value	Multivariate odds ratio (95% CI)†
HCV serotype (1 vs 2)	0.002	8.743 (2.215-34.517)
Presence of DM	0.014	8.657 (1.462-51.276)

†Values are the odds of having difficulty becoming a sustained-responder.
CI, confidence interval; DM, diabetes mellitus; HCV, hepatitis C virus.

that influences the ability to achieve SVR. However, in our patients, the liver histological staging of patients with DM tended to be higher than that of patients without DM, but no significant difference was detected. In addition, the presence of DM did not affect the HCV viral load, ALT levels, or liver histological activity. Multiple logistic regression analysis revealed that the presence of DM and HCV serotype 1, but not liver histological staging, was an independent factor affecting the therapeutic efficacy.

The mechanism by which DM interferes with viral elimination in CHC patients remains unclear. Recently, it was reported that insulin resistance impaired the virological response to peg-IFN plus ribavirin treatment;[18] the insulin resistance index has been found to be an independent factor for achieving a sustained response. Insulin resistance has been shown to be caused by increased production levels of tumor necrosis factor (TNF)-α. In fact, the production of TNF-α is increased in chronic liver injury,[27] and TNF-α is one of the causes of DM in CHC patients.[28-30] A study of a mouse model transgenic for the HCV core gene revealed that HCV caused insulin resistance, and the presence of a high TNF-α level was considered to be one of the factors leading to insulin resistance in the transgenic mice.[31] Furthermore, the baseline TNF-α values in sustained-responders have been found to be significantly lower than in non-responders.[32,33] TNF-α inhibits IFN-α signaling by stimulating the expression of the suppressor of cytokine signaling proteins.[34] In this context, TNF-α is important not only for the development of DM but also for interfering with the elimination of HCV in CHC patients. Thus, in our DM patients, TNF-α could have reduced their response to IFN-α2b plus ribavirin therapy. However HOMA-IR did not differ between sustained-responders and non-responders. Our sample size is too small to evaluate the relationship between insulin resistance and the response to IFN-α2b plus ribavirin therapy. However, fasting blood glucose and HbA1c were significantly higher in DM patients than in patients without DM. In particular, no patient with an HbA1c higher than 6.9% became a sustained-responder. Thus, our results indicate that, in addition to insulin resistance, the level of hyperglycemia is an important factor that interferes with HCV elimination. Hyperglycemia causes increased production of advanced glycation end products, which induce oxidative stress and cytokines, such as TNF-α and interleukin, by combining with their receptors.[35-37] In this manner, hyperglycemia may render IFN-α2b plus ribavirin therapy ineffective.

In conclusion, our study revealed that DM and HCV serotype 1 were independent factors that reduced the rate of viral elimination in CHC patients given combined therapy. However, the mechanism responsible for the reduction of viral elimination in DM patients could not be identified. Further studies are needed to determine how the presence of DM affects viral elimination.

Not only hyperglycemic state of DM but also insulin resistance can be improved by suitable diet therapy, exercise, insulin and other hypoglycemic agents. Hepatologists who initiate antiviral therapy should consult with DM specialists and dietitians before or during antiviral therapy of CHC patients with DM. An improvement of hyperglycemia and insulin resistance can lead to good response of antiviral therapy of CHC patients with DM.

REFERENCES

1 Saito I, Miyamura T, Ohbayashi A *et al.* Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. *Proc Natl Acad Sci USA* 1990; 87: 6547–9.
2 McHutchison JG, Gordon SC, Schiff ER *et al.* Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485–92.
3 Davis GL, Esteban-Mur R, Rustgi V *et al.* Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1493–9.
4 Tsubota A, Chayama K, Ikeda K *et al.* Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. *Hepatology* 1994; 19: 1088–94.
5 Martinot-Peignoux M, Marcellin P, Pouteau M *et al.* Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. *Hepatology* 1995; 22: 1050–6.
6 Enomoto N, Sakuma I, Asahina Y *et al.* Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; 334: 77–81.
7 Horiike N, Michitaka K, Masumoto T *et al.* Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene. *J Gastroenterol Hepatol* 1999; 14: 345–51.
8 Horiike N, Masumoto T, Nakanishi K *et al.* Interferon therapy for patients more than 60 years of age with chronic hepatitis C. *J Gastroenterol Hepatol* 1995; 10: 246–9.
9 Matsushita M, Hijikata M, Matsushita M *et al.* Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. *J Hepatol* 1998; 29: 695–700.